SCHEMBL30307339

SCHEMBL30307339

CCOc1ccc2[nH]c(=O)c(CN(Cc3ccco3)C(=O)c3cccs3)cc2c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 17/20 0.77
ALDH1A1 P00352 15/20 0.73
HSD17B10 Q99714 11/20 0.73
PKM P14618 4/20 0.73
RECQL P46063 1/20 0.73
TSHR P16473 4/20 0.72
NPSR1 Q6W5P4 4/20 0.72
MAPT P10636 3/20 0.72
HPGD P15428 7/20 0.70
HTT P42858 4/20 0.70
LMNA P02545 3/20 0.70
MAPK1 P28482 1/20 0.70
ALOX15 P16050 5/20 0.69
NPC1 O15118 1/20 0.69
USP2 O75604 1/20 0.69
GAA P10253 1/20 0.68
SMN1; SMN2 Q16637 3/20 0.64
KMT2A Q03164 1/20 0.64
CYP1A2 P05177 2/20 0.63
CYP3A4 P08684 2/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12595343 0.87 KDM4E (0.79) KDM4EALDH1A1HSD17B10TSHRNPSR1
SCHEMBL13496428 0.87 KDM4E (1.00) KDM4EALDH1A1HSD17B10PKMRECQL
SCHEMBL12595339 0.84 KDM4E (0.73) KDM4EALDH1A1HSD17B10TSHRNPSR1
SCHEMBL13496443 0.84 KDM4E (1.00) KDM4EALDH1A1HSD17B10TSHRNPSR1
SCHEMBL12594151 0.83 ALDH1A1 (0.77) KDM4EALDH1A1HSD17B10TSHRNPSR1
SCHEMBL12594568 0.83 KDM4E (0.82) KDM4EALDH1A1HSD17B10TSHRNPSR1
SCHEMBL12594558 0.83 ALDH1A1 (1.00) KDM4EALDH1A1HSD17B10TSHRNPSR1
SCHEMBL30307323 0.79 ALDH1A1 (0.70) KDM4EALDH1A1HSD17B10PKMTSHR
SCHEMBL13496405 0.78 ALDH1A1 (1.00) KDM4EALDH1A1HSD17B10PKMRECQL
SCHEMBL12594152 0.77 ALDH1A1 (0.73) KDM4EALDH1A1HSD17B10TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366586-A1 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-11-07 US claimed
WO-2023034413-A2 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-09 WO claimed
US-20240366586-A1 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-11-07 US disclosed
WO-2023034413-A2 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366586-A1 METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE IL15, IL2, IL17A KDM4E 1626/4885ALDH1A1 3528/4885HSD17B10 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.